BrightSpring Health Services
BTSG
63.80
+0.05
+0.08%
BrightSpring Health Services
US · BTSG
#1332 by market cap
Listed 2024
63.80
+0.05
+0.08%
Live - 5344 symbols - heartbeat 103s ago
· 2026-10-08 08:31
Pre-market
63.80
0.00%
After-hours
64.75
+1.49%
Overnight
64.04
+0.38%
- Market cap
- 12.62B
- P/E (TTM)i
- 38.67
- P/Bi
- 6.16
- EPSi
- 0.87
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on BTSG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.02, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +28.18% YoY
Margins
- Gross margin
- 11.76%
- Operating margin
- 2.29%
- Net margin
- 1.48%
Key ratios & quality
- Enterprise valuei
- 15.09B
- Altman Z-Scorei
- 4.02
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.54B | 4.53B | 5.58B | 6.70B | 7.72B | 7.69B | 10.07B | 12.91B |
| Gross profit | 375.91M | 833.91M | 1.05B | 1.25B | 1.35B | 1.14B | 1.27B | 1.52B |
| Selling & admin expenses | 312.13M | 770.59M | 883.55M | 1.01B | 1.13B | 1.08B | 1.16B | 1.22B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 63.78M | 63.31M | 165.19M | 234.18M | 228.69M | 58.13M | 107.95M | 295.25M |
| Pretax profit | -10.83M | -103.58M | 26.24M | 68.86M | -45.75M | -213.77M | -95.32M | 137.94M |
| Tax | -3.21M | -32.49M | 5.09M | 17.60M | 8.47M | -31.51M | -26.39M | 33.15M |
| Net profit | -7.62M | -71.09M | 21.15M | 51.26M | -54.22M | -156.84M | -20.52M | 189.11M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 1 |
| Diluted EPS | -0.04 | -0.42 | 0.12 | 0.29 | -0.31 | -0.90 | -0.09 | 0.87 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.88B | 3.15B | 3.33B | 3.55B | 3.61B | 3.87B |
| Gross profit | 338.37M | 374.85M | 392.01M | 412.55M | 482.22M | 492.75M |
| Selling & admin expenses | 287.63M | 326.30M | 304.17M | 304.44M | 360.77M | 362.36M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 50.74M | 48.56M | 87.84M | 108.11M | 121.45M | 130.39M |
| Pretax profit | 8.98M | 9.78M | 49.61M | 69.58M | 82.83M | 93.51M |
| Tax | -240.00K | 1.24M | 12.12M | 20.03M | 8.55M | 6.91M |
| Net profit | 29.01M | 27.54M | 55.24M | 77.32M | 148.61M | 84.21M |
| Basic EPS | 0 | 0 | 0 | 0 | 1 | 0 |
| Diluted EPS | 0.14 | 0.13 | 0.26 | 0.35 | 0.67 | 0.38 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 870.68M | 1.29B | 1.18B | 1.34B | 1.46B | 1.89B | 2.89B |
| Cash & ST investments | -- | 18.30M | 262.01M | 46.74M | 13.63M | 13.07M | 60.95M | 88.37M |
| Inventory | -- | 198.47M | 300.06M | 299.22M | 430.52M | 402.78M | 636.56M | 815.18M |
| Total assets | -- | 3.82B | 4.54B | 5.51B | 5.44B | 5.53B | 5.93B | 6.41B |
| Total current liabilities | -- | 621.97M | 742.79M | 892.16M | 932.51M | 1.25B | 1.43B | 1.85B |
| Short-term debt | -- | 89.50M | 91.01M | 125.22M | 107.86M | 114.47M | 91.10M | 102.07M |
| Long-term debt | -- | 2.16B | 2.67B | 3.39B | 3.36B | 3.33B | 2.56B | 2.46B |
| Total liabilities | -- | 3,107,108,000.00 | 3,805,698,000.00 | 4,712,677,000.00 | 4,657,056,000.00 | 4,920,172,000.00 | 4,274,555,000.00 | 4,526,945,000.00 |
| Total equity | -- | 710.23M | 735.38M | 800.46M | 784.08M | 612.55M | 1.65B | 1.89B |
| Retained earnings | -- | -94.28M | -51.75M | 971.00K | -45.72M | -200.32M | -222.16M | -74.65M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.53B | 2.65B | 2.78B | 2.89B | 2.69B | 2.47B |
| Cash & ST investments | 52.34M | 70.07M | 140.34M | 88.37M | 888.80M | 550.38M |
| Inventory | 533.64M | 625.47M | 639.20M | 815.18M | 560.17M | 575.01M |
| Total assets | 5.85B | 5.94B | 6.05B | 6.41B | 6.21B | 5.99B |
| Total current liabilities | 1.46B | 1.51B | 1.55B | 1.85B | 1.55B | 1.56B |
| Short-term debt | 90.70M | 93.20M | 94.81M | 102.07M | 105.09M | 93.02M |
| Long-term debt | 2.49B | 2.48B | 2.47B | 2.46B | 2.44B | 2.15B |
| Total liabilities | 4,156,378,000.00 | 4,198,174,000.00 | 4,228,479,000.00 | 4,526,945,000.00 | 4,223,421,000.00 | 3,927,515,000.00 |
| Total equity | 1.69B | 1.75B | 1.82B | 1.89B | 1.99B | 2.06B |
| Retained earnings | -192.61M | -164.41M | -108.57M | -74.65M | 14.14M | 38.43M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 76.45M | 110.91M | 222.64M | 270.17M | -4.65M | 210.78M | 23.77M | 490.17M |
| Depreciation & amortization | 81.17M | 154.87M | 181.50M | 199.16M | 203.97M | 202.34M | 204.48M | 164.28M |
| Free cash flow | 43.25M | 59.69M | 170.73M | 210.90M | -74.77M | 137.26M | -57.14M | 394.69M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 261.14M | -1.12M | 12.39M | 0 | -650.00K | 1.04B | -43.17M |
| Ending cash balance | 30.52M | 18.30M | 262.01M | 46.74M | 13.63M | 13.07M | 61.25M | 88.48M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 101.60M | 49.08M | 107.94M | 231.56M | 122.94M | 43.92M |
| Depreciation & amortization | 42.16M | 41.84M | 40.75M | 39.52M | 39.09M | 41.42M |
| Free cash flow | 83.97M | 24.65M | 92.17M | 193.89M | 101.40M | 14.88M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | -43.17M | -60.00M | -60.00M |
| Ending cash balance | 52.64M | 70.23M | 141.30M | 88.48M | 888.80M | 550.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -11.02 | 3.06 | 6.73 | -7.05 | -23.08 | -1.62 | 10.82 |
| ROA %i | -- | -1.90 | 0.50 | 0.99 | -0.98 | -2.82 | -0.32 | 3.09 |
| ROIC %i | -- | 1.38 | 3.92 | 4.20 | 2.91 | 3.05 | 3.69 | 6.79 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -6.27 | -4.39 | -2.84 |
| EBIT margin %i | 2.52 | 1.40 | 2.96 | 3.50 | 2.43 | 1.67 | 1.72 | 2.29 |
| FCF / sales %i | 1.71 | 1.32 | 3.06 | 3.15 | -- | 1.56 | -- | 3.06 |
| Current ratioi | -- | 1.40 | 1.74 | 1.32 | 1.44 | 1.17 | 1.33 | 1.57 |
| Quick ratioi | -- | 1.03 | 1.30 | 0.95 | 0.95 | 0.82 | 0.76 | 0.63 |
| Debt / assetsi | -- | 64.01 | 65.50 | 68.39 | 67.58 | 66.34 | 47.06 | 42.21 |
| LT debt / equityi | -- | 358.36 | 408.99 | 470.48 | 472.88 | 608.15 | 163.72 | 138.94 |
| Interest coveragei | 0.85 | 0.38 | 1.19 | 1.42 | 0.80 | 0.45 | 0.85 | 1.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 38.23 | 19.49 | 11.29 | 14.57 | 18.69 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | 69.57 | -- | -7.02 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 3.52 | 3.92 | 7.55 | 10.82 | 16.90 | 19.30 |
| ROA %i | 1.00 | 1.13 | 2.19 | 3.09 | 5.14 | 6.14 |
| ROIC %i | 5.13 | 4.42 | 6.33 | 6.79 | 9.55 | 11.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.30 | 2.25 | 2.56 | 2.29 | 2.68 | 3.12 |
| FCF / sales %i | 1.08 | 1.52 | 2.08 | 3.06 | 3.02 | 2.80 |
| Current ratioi | 1.73 | 1.76 | 1.79 | 1.57 | 1.74 | 1.59 |
| Quick ratioi | 0.77 | 0.76 | 0.80 | 0.63 | 1.35 | 1.19 |
| Debt / assetsi | 46.47 | 45.63 | 44.62 | 42.21 | 43.45 | 39.89 |
| LT debt / equityi | 155.64 | 150.25 | 143.22 | 138.94 | 131.09 | 112.00 |
| Interest coveragei | 1.26 | 1.34 | 1.68 | 1.88 | 2.37 | 2.94 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Pharmacy Solutions is the largest reported line at 87.97% of revenue, across 2 reported segments.
- The next-largest line, Provider Services, is a distant second at 12.03% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Pharmacy Solutions87.97%
Provider Services12.03%
Quote time 2026-10-08 08:31:16 · For reference only, not investment advice and not tailored to your situation.